Discontinuation of iv bapineuzumab places solanezumab under scrutiny
This article was originally published in Scrip
Executive Summary
Having failed to meet its co-primary endpoints in the second of four Phase III trials, development of iv bapineuzumab in Alzheimer's disease has been abandoned. Discontinuation of this eagerly anticipated candidate will reignite debate surrounding the appropriateness of targeting beta amyloid in cases where plaques are already present, and shine the spotlight firmly on Lilly's solanezumab, says Datamonitor's Charlotte Mackey.
You may also be interested in...
Potential first-to-market long acting levodopa combo from Impax/GSK shows promise in PD
Impax and GlaxoSmithKline have announced that IPX066 has demonstrated a statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of “off-time” in the ASCEND-PD Phase III trial of Parkinson’s disease patients (Scripintelligence.com, 15 August, 2011). The strength of the extended release cabidopa-levodopa formulation lies in its increased "off time" compared to immediate-release formulations, reduced motor symptoms, and less frequent administration. However, the pricing strategy for IPX066 will have a critical bearing on the drug’s commercial success.